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Abstract 
Human Vγ9/Vδ2 T-cells detect tumour cells and microbial infections by recognising small 
phosphorylated prenyl metabolites termed phosphoantigens (P-Ag). The type-1 transmembrane 
protein Butyrophilin 3A1 (BTN3A1) is critical to the P-Ag-mediated activation of Vγ9/Vδ2 T-cells, 
however, the molecular mechanisms involved in BTN3A1-mediated metabolite sensing are unclear, 
including how P-Ag are discriminated from non-antigenic small molecules. Here, we utilised NMR and 
X-ray crystallography to probe P-Ag sensing by BTN3A1. Whereas the BTN3A1 Immunoglobulin 
Variable domain failed to bind P-Ag, the intracellular B30.2 domain bound a range of negatively-
charged small molecules, including P-Ag, in a positively-charged surface pocket. However, NMR 
chemical shift perturbations indicated BTN3A1 discriminated P-Ag from non-antigenic small 
molecules by their ability to induce a specific conformational change in the B30.2 domain that 
propagated from the P-Ag binding site to distal parts of the domain. These results suggest BTN3A1 
selectively detects P-Ag intracellularly via a conformational antigenic sensor in its B30.2 domain, and 
have implications for rational design of antigens for Vγ9/Vδ2 -based T-cell immunotherapies.  
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Introduction 
Vγ9/Vδ2 T cells represent the dominant subtype of human γδ T cells in adult peripheral blood (1). 
Present since birth (2), this subset expands in response to a number of different infections, including 
tuberculosis, leprosy, typhoid, malaria, and toxoplasmosis, and studies in primate models have 
suggested a role in immunity to Mycobacterium tuberculosis (3). In addition, they are also capable of 
in vitro recognition of a diverse range of cancer cells (1). Target cell recognition is dependent on their 
Vγ9/Vδ2 T cell receptor (TCR) (4), and is also cell-cell contact-dependent, but is MHC-independent 
(5, 6). Vγ9/Vδ2 T cells display potent effector capacity, including cytotoxicity and production of IFN-γ 
and TNFα (7, 8). Based on their universal presence in humans, proliferative capacity, potential 
implication in both pathogen-specific and tumour-specific immunity, MHC-unrestricted target cell 
recognition, and pharmacological manipulability (see below), Vγ9/Vδ2  T cells have become the 
dominant focus for therapeutic exploitation of γδ T cells (9).  
Unlike classical αβ T cells, Vγ9/Vδ2 T cells are activated by non-peptidic pyrophosphate 
(diphosphate) antigens (P-Ag), of which the first to be identified was isoprenyl 
pyrophosphate/diphosphate (IPP) (10), a compound all organisms, including humans, use to 
synthesise isoprenoid compounds, and which in eukaryotes is generated via the mevalonate and non-
mevalonate pathways. However, the second non-mevalonate or MEP pathway utilised by most 
eubacteria, some protozoa and cyanobacteria but not humans, generates hydroxy-3-methyl-but-2-
enyl pyrophosphate/disphosphate (HMBPP) (11), a potent stimulator of Vγ9/Vδ2 T cell responses. 
The ~30,000 increased potency of HMBPP over IPP suggests that in normal situations it may enable 
Vγ9/Vδ2 T cells to distinguish exogenous microbial (7) from endogenous host P-Ag(10).  However, a 
number of studies have highlighted spontaneous recognition of cancer cell lines by Vγ9/Vδ2 T cells 
(5, 12), a phenomenon that likely relates to increased IPP levels in such cells (8). Moreover, 
pharmacological inhibitors of IPP catabolism, including clinically used aminobisphosphonates such as 
Zoledronate (13-15), are known to sensitize target cells, including cancer cells, for Vγ9/Vδ2 T cell 
recognition via accumulation of IPP.  Therefore, uniquely for a T cell subset, the antigen-driven 
effector responses of Vγ9/Vδ2 T cells are pharmacologically manipulable.  
Despite being the subject of strong therapeutic interest, Vγ9/Vδ2 T cells recognise target cells via a 
TCR- and P-Ag-dependent mechanism the details of which remain largely unclear. One important 
advance has been the identification of the butyrophilin-like molecule BTN3A1 as a critical mediator of 
P-Ag sensing (16, 17). BTN3A1 is a type 1 transmembrane protein consisting of an ectodomain 
comprising a membrane distal variable-like domain, a membrane proximal constant-like 
immunoglobulin domain, a single transmembrane spanning region, and an intracellular B30.2 domain 
(Figure S1a) (18, 19). Nevertheless, opposing mechanisms have been proposed to explain how 
BTN3A1-mediated P-Ag sensing takes place. Based partly on crystallographic data, Vavassori et al  
suggested direct presentation of P-Ag including IPP and HMBPP to Vγ9/Vδ2 T cells by the 
membrane-distal variable-like domain within the BTN3A1 ectodomain (17). In contrast, a number of 
studies have instead proposed that BTN3A1 acts as an intracellular P-Ag sensor, initiated by P-Ag 
binding to the intracellular B30.2 domain of BTN3A1 (19-21). Despite these studies, the molecular 
events proximal to P-Ag interaction are entirely unclear.  
Understanding the molecular mechanisms underlying BTN3A1’s role in P-Ag sensing will enhance 
understanding of Vγ9/Vδ2 T cell recognition and could suggest novel immunotherapeutic strategies. 
In this study, we present data that suggest BTN3A1 acts as an intracellular metabolite sensor capable 
of triggering downstream activation events via a conformational change in its cytosolic B30.2 domain, 
which occurs selectively in response to P-Ag but not non-antigenic small molecules (Figure S1b).  
 
 
 Results and Discussion 
Antigenic pyrophosphates selectively bind to the B30.2 domain of BTN3A1  
	
Since the mode of P-Ag interaction with BTN3A1 has been controversial (17, 20) we first sought to 
test if we could detect P-Ag binding to the BTN3A1 IgV-like domain, and to the B30.2 domain, as well 
as locate the identity of putative binding sites. We applied nuclear magnetic resonance (NMR) studies 
to test interaction of P-Ag with the membrane-distal Variable-like domain of BTN3A1, and separately, 
with the intracellular B30.2 domain. NMR provided a powerful methodology not only to confirm 
interaction, but also potentially to map sites of interaction on the protein surface. First, the IgV-domain 
was expressed in E. coli and subjected to 1H-15N NMR in the absence and presence of HMBPP and 
the more stable phosphonate analogue, cHDMAPP (22). High quality spectra were detected, which 
allowed us to assign all residues in the 1H-15N HSQC spectrum of the IgV domain, including those 
purported to bind HMBPP/IPP based on a previous crystallographic study (17). However, despite the 
use of relatively high P-Ag concentrations (1.5 mM), we failed to identify any chemical shift 
perturbations in the presence of HMBPP (Figure 1) or cHDMAPP (Figure S2). This included residues 
in the proposed P-Ag binding site, for which well resolved peaks in the HSQC spectra were 
observable both in the absence and presence of P-Ag. This indicated a lack of interaction of 
biologically highly potent P-Ag with BTN3A1 IgV-like domain, including residues E64, K66, R88, 
Y127, Q129 and Y134 (residue numbering is based on Uniprot accession code O00481) previously 
highlighted by Vavassori and colleagues as interacting with IPP/HMBPP. 
We then tested P-Ag interaction with the B30.2 domain of BTN3A1, employing a similar NMR-based 
approach, using B30.2 protein recombinantly expressed in 1H-15N-labelled form in E. coli. In contrast 
to analyses with the V-like domain, 1H-15N NMR experiments using the intracellular B30.2 domain 
indicated substantial chemical shift changes in numerous B30.2 residues in the presence of P-Ag, 
indicating direct interaction (Figure 2, Figure S3). Notably, broadly similar chemical shift 
perturbations were observed with HMBPP (Figure S3a) and cHDMAPP (Figure 2). In contrast, 
smaller chemical shift perturbations were observed following titration with IPP (Figure S3b). 
Collectively, these studies confirmed that P-Ag selectively bind to the intracellular B30.2 domain, but 
do not bind to the extracellular IgV-like domain.  
	
The B30.2 domain is capable of binding negatively charged small molecules 
	
To understand the structural basis of P-Ag/B30.2 interaction, we attempted to crystallise the B30.2 
domain with cHDMAPP, exploring co-crystallisation strategies and a wider range of crystallisation 
conditions than have previously been published (20). We obtained high quality crystals in a range of 
conditions that differed from previous structural analyses, and collected 1.6Å and 1.7Å diffraction data 
on crystals from two such conditions (Table S1). These showed unequivocal electron density for a 
small molecule moiety, in each case within a positively charged surface pocket, incorporating 
residues H381, R442, R448 and R499 (Figure 3a-d). However, early inspection of the electron 
density revealed a poor fit to HMBPP, whereas the density fitted closely to malonate and citrate, 
present in the crystallisation conditions for the 1.6Å and 1.7Å datasets respectively (Figure 3a-d). 
This confirmed that these structures represented serendipitous co-crystal structures of the B30.2 
domain with malonate and citrate, neither of which has previously been highlighted as activating 
antigens for Vγ9Vδ2 T cells. Superimposition with the cHDMAPP-soaked and glutaraldehyde-cross 
linked structure of Sandstrom et al indicated that the bound malonate and citrate moieties overlapped 
strikingly with the proposed position of cHDMAPP (Figure 3e), appearing to interact with essentially 
the same electropositive surface patch on the B30.2 domain and mediating a network of hydrogen-
bonding interactions with neighbouring B30.2 residues (Figure 3f-h). 
Importantly, superimposition of these malonate and citrate B30.2 co-crystal structures with previous 
apo structures demonstrated strong similarities, with backbone rms deviations of 0.229Å (for 187 
aligned Cα atoms) and 0.171Å (for 187 aligned Cα atoms), respectively (Figure 3i). In addition, very 
few conformational alterations were evident around the binding site, aside from minor adjustments in 
neighbouring side chains, although we could not formally discount the possibility that crystal contacts 
constrained possible conformational changes from being detected. These data proved unequivocally 
that the proposed HMBPP binding site within the B30.2 domain is able to bind a range of negatively 
charged small molecules, including the negatively charged small molecules malonate and citrate, 
which are not thought to activate Vγ9/Vδ2  T cells. However they raised the question of how antigenic 
versus non-antigenic small molecules are discriminated by the B30.2 domain.   
	
B30.2 chemical shifts distinguish P-Ag from non-antigenic molecule binding 
	
Previously it has been suggested that instead of being presented directly by the BTN3A1 IgV-like 
ectodomain, P-Ag may induce a conformational change in the B30.2 domain, based partly on the 
observation that B30.2 apo crystals soaked in cHDMAPP dissolved (20). To determine to what extent 
P-Ag and non-antigenic small molecules could induce conformational alterations in the B30.2 domain 
in solution, we used NMR to titrate each ligand against the apo form of BTN3A1 B30.2 domain and 
analyse subsequent chemical shift perturbations.  We then went on to map NMR chemical shifts 
observed in the B30.2 domain upon P-Ag binding (Figure 4), and compare them to those induced in 
the presence of malonate (Figure 5) and citrate (Figure S4). As highlighted above, extensive 
chemical shifts relative to the apo B30.2 were observed upon HMBPP/cHDMAPP exposure (Figure 2, 
Figure S3). Assignment of the 1H-15N HSQC spectrum indicated that residues undergoing chemical 
shifts included several clustered close to the previously proposed P-Ag binding site (20). In addition, 
the detection of chemical shifts in residues protruding from the β2-β3 loop (K366 and Q369), β5 
strand (S413), β3-β4 loop (F390 and I391), β5-β6 loop (K419, G420 and N428), β6 strand (G429 and 
W431) and the β6-β7 loop (G438), which were distal to this site, confirmed that P-Ag binding had 
induced conformational changes in the B30.2 domain that extended beyond the immediate P-Ag 
interaction site (Figure 4a-b). In comparison, IPP induced similar chemical shift perturbations as to 
those observed with HMBPP and cHDMAPP, although these shifts were qualitatively smaller in 
magnitude (Figure 4c). 
In contrast, titration of the B30.2 domain with malonate and citrate revealed only a small number of 
chemical shift perturbations compared to the apo structure (Figure 5a, Figure S4a). In addition, these 
were small in magnitude, and in residues located close to the citrate/malonate binding site observed 
in crystallographic studies. However, unlike HMBPP/cHDMAPP, both malonate and citrate failed to 
induce perturbations in residues more distal to the proposed HDMAPP binding site, notably K366, 
Q369, F390, I391, S413, K419, N428, G429 and W431 (Figure 5b, Figure S4b). These data 
indicated that unlike P-Ag, alterations induced in B30.2 by citrate or malonate binding are restricted to 
regions close to the small molecule interaction site.  
We next sought to directly confirm whether citrate and malonate were able to stimulate Vγ9/Vδ2 T 
cells or not. To do this, we compared the functional responsiveness of human peripheral blood 
Vγ9/Vδ2 T cells and CD8+ T cells (Figure 6a) to citrate, malonate and P-Ag indicated to bind the 
BTN3A1 B30.2 domain. While Vγ9/Vδ2 T cells responded to known P-Ags cHDMAPP and IPP 
(Figure 6b), neither citrate nor malonate were capable of stimulating the upregulation of T cell 
activation markers, CD25 and CD69 in Vγ9/Vδ2 T cells (23-25) (Figure 6c). Moreover, while CD8+ T 
cells showed no appreciable response to any molecule tested (Figure 6d), Vγ9/Vδ2 T cells required 
~8000 fold less cHDMAPP (EC50 = 1.2 nM) than IPP (EC50 = 7783 nM)  to induce similar activation 
levels of CD25 and CD69 (Figure 6e). Taken together, these data indicate that while a range of small 
molecules are able to bind the BTN3A1 B30.2 domain, only structures very closely related to the 
microbially-derived diphosphate antigen, HMBPP, appear capable of activating human Vγ9/Vδ2 T 
cells. 
As neither malonate nor citrate resembles traditional P-Ags, we sought to investigate other potential 
ligands. The nucleotide Adenosine diphosphate (ADP; also known as Adeonsine pyrophosphate) is 
an important molecule in cellular metabolism and also has a role in activation of blood platelets. 
Similarly to HMBPP and IPP it contains a diphosphate headgroup, but differs in the hydrocarbon 
chain as it is linked to a pentose sugar and adenine nitrogenous base (Figure S1b). 1H-15N HSQC 
experiments showed that ADP caused widespread chemical shift perturbations on interaction with the 
B30.2 domain (Figure S5a), and when mapped these shifts were found to be around the previously 
proposed binding site in addition to the periphery of the molecule, suggesting that as for HMBPP or 
IPP, it also induced an overall conformational change (Figure S5b-c). We repeated our earlier 
experiments in order to assess the stimulatory capacity of ADP on Vγ9/Vδ2 T cells. However, unlike 
HMBPP or IPP, ADP was found to be incapable of activating Vγ9/Vδ2 T cells at a range of 
concentrations similar to citrate and malonate (Figure 6f). Further analysis of the chemical shift 
perturbations detected with the addition of ADP showed that a number of shifts occurred in a different 
direction compared to those with HMBPP or IPP, suggesting that the conformational change induced 
by ADP may be qualitatively different compared to that induced by HMBPP or IPP.  
 
In silico modelling of small molecule interaction with the B30.2 domain 
	
The disparity between the activation potential of each diphosphate containing molecule suggests that 
the hydrocarbon tail is also important in inducing activation. To help rationalise interaction of small 
molecule binding to the B30.2 domain, we initially performed in silico docking of both cHDMAPP and 
IPP into the crystal structure of the B30.2 domain. Interestingly, both compounds were docked into 
the same site confirmed by the NMR studies as the site involved in binding negatively charged small 
molecules (Figure 7a-b). Indeed, the diphosphate headgroup of cHDMAPP and IPP was docked into 
the positively charged site and formed key interactions with three arginine residues (R442, R448 and 
R499). Intriguingly, the free hydroxyl group of cHDMAPP was predicted to form a hydrogen bond with 
H381, an interaction unique to cHDMAPP (Figure 7a) and not IPP as it lacks this free hydroxyl 
(Figure 7b). Notably, this interaction was not observed in the co-crystal structure of B30.2 with 
cHDMAPP as the organic chain lacked resolvable electron density (20). Subsequent similar in silico 
docking of malonate and citrate indicated that these compounds docked well into the positively 
charged pocket where the diphosphate head of HMBPP and IPP fitted (data not shown). Similar key 
residues within this pocket, namely R442 and R499, which the diphosphate group interacted with, 
also formed hydrogen bonds with the citrate and malonate ligands. Consistent with its status as the 
most potent Vγ9/Vδ2 T-cell activator, HMBPP showed a more favourable binding free energy (-15.57 
kcal/mol) compared to IPP (-14.79 kcal/mol). Moreover, the binding free energies for citrate and 
malonate were considerably less favourable than either P-Ag (-9.79 kcal/mol and -7.67 kcal/mol, 
respectively), suggesting they may have a substantially reduced affinity.  
To investigate the role of H381 and the neighbouring hydrophobic residue Y382 in the activation of 
Vγ9/Vδ2 T cells we generated a series of BTN3A1 B30.2 mutants, using site directed mutagenesis to 
substitute each residue for either an alanine or a similar amino acid (H381R and Y382F). Firstly, 
CRISPR/Cas9 empty vector HEK293T cells pulsed with zoledronate were capable of the activation of 
a short term Vδ2+ T cell line expanded from human PBMCs (Figure 8a). However, zoledronate pulsed 
CRISPR/Cas9 BTN3A1 knock-out HEK293T cells were unable to support activation of Vδ2+ T cells 
(Figure 8a). Reintroduction of wild type (WT) BTN3A1 by transient transfection into BTN3A1 knock-
out HEK293T cells rescued zoledronate mediated Vδ2+ T cells activation (Figure 8a). Next, we 
expressed each mutant construct in BTN3A1 knock-out HEK293T cells treated with Zoledronate and 
assessed Vδ2+ T cell activation (Figure 8b). We evaluated the abrogation of CD25 expression on 
Vδ2+ T cells by each BTN3A1-mutant through normalising the percentage of CD25+ Vδ2+ T cells to 
the wild-type BTN3A1 T cell response. This analysis revealed that H381A, H351R and Y382A 
reduced the activation of Vδ2+ T cells by >50% of that of WT BTN3A1. Interestingly, BTN3A1 H381R 
showed >90% reduction in Vδ2+ T cells activation to that of the WT BTN3A1, while the BTN3A1 
Y382F mutant could support  >60% of the activation observed for WT BTN3A1 (Figure 8c).  
We then recombinantly expressed the B30.2 domain incorporating these mutations and analysed 
interactions with diphosphate ligands. 1H-15N HSQC experiments confirmed that BTN3A1 B30.2 
H381A, Y382A and Y382F were similarly folded, however BTN3A1 B30.2 H381R was remarkably 
unstable and quickly precipitated, and so was unsuitable for these experiments. We observed a 
difference when comparing H381A and Y382A to WT, in terms of chemical shift perturbations (Figure 
S6) upon P-Ag binding. Our in silico experiments had predicted that the interaction between B30.2 
H381A and HMBPP would be reduced to levels comparable to IPP; however experimentally we 
observed greatly reduced chemical shift perturbations in terms of number and magnitude with both 
HMBPP and IPP. Similarly, Y382A also showed a reduction with IPP, however the shifts observed 
with HMBPP was relatively unaffected. In comparison, little change was seen in chemical shift 
perturbations induced in B30.2 Y382F, with some exceptions. These results may reflect differences 
between molecular components involved in initial P-Ag interaction and subsequent conformational 
rearrangements.  Importantly, these experiments directly implicate pocket residues in mediating the 
specific conformational change triggered by P-Ag binding.  
While BTN3A1 is now acknowledged to be a critical mediator of antigen recognition by Vγ9/Vδ2 T 
cells, the molecular basis by which it sensitizes P-Ag-exposed target cells for  recognition by this T 
cell subset is still unclear (26). Studies published within the last 3 years have proposed opposing 
models. Vavassori et al presented crystal structures of the BTN3A1 IgV-like domain incorporating 
electron density supposedly matching IPP or HMBPP, combined with SPR data purporting to 
demonstrate interaction of a Vγ9/Vδ2 TCR with the BTN3A1 IgV, which only appeared to be 
marginally enhanced in affinity in the presence of IPP/HMBPP (17). However, Sandstrom et al 
challenged key elements of these findings, noting that the electron density purportedly representing 
IPP/HMBPP instead matched that of a crystallisation component, polyethylene glycol(20). In addition, 
Sandstrom et al failed to replicate TCR binding to the IgV-like domain, in the presence or absence of 
IPP/HMBPP, and instead presented evidence for P-Ag binding directly to the intracellular B30.2 
domain. Also, subsequent studies by Wang et al and Rhodes et al have also supported an 
intracellular sensor function (19, 21). The aim of the current study was to shed light on the molecular 
events proximal to P-Ag interaction with BTN3A1.   
Using NMR spectroscopy, we failed to detect any interaction of P-Ag with the IgV-like domain, despite 
detecting strong resonances for residues of the putative IPP/HMBPP binding site proposed by 
Vavassori et al. This casts further doubt on the findings of Vavassori et al (17). In contrast, we 
observed strong signals denoting direct interaction of P-Ag with the intracellular B30.2 domain, as 
evidenced by numerous chemical shifts upon P-Ag exposure. This strongly supports previous data 
(20, 27), confirming that P-Ags directly interact with BTN3A1, and that this occurs solely via the B30.2 
domain, and not via the IgV-like domain. Since the B30.2 domain is within the intracellular region of 
BTN3A1, this adds to the growing body of evidence that instead of ‘presentation of altered self’ by its 
IgV-like domain, the BTN3A1 B30.2 domain is a critical player in an intracellular sensing mechanism 
that translates cytosolic P-Ag exposure in target cells into the ability to stimulate Vγ9/Vδ2 T cells in a 
TCR-dependent manner (19-21). 
Our study sheds significant light on the region of B30.2 involved in P-Ag binding. Previously, an 
electropositive surface patch on the B30.2 domain was highlighted as a putative P-Ag binding site by 
the ‘soaking’ of glutaraldehyde-crosslinked apo B30.2 domain crystals with cHDMAPP. Notably, the 
only interpretable electron density for the cHDMAPP moiety in this structure was the pyrophosphate 
headgroup. In addition, a recent extensive mutagenesis study of BTN3A1 highlighted the functional 
importance of a set of residues clustered around this putative site in P-Ag-mediated Vg9Vδ2 
activation (21). Our NMR data are consistent with this proposed binding site, since several of the 
chemical shifts we observed upon P-Ag binding cluster around this pocket. Indeed, several amino 
acids proximal to the site highlighted by Wang et al(21) as functionally important in P-Ag sensing 
underwent detectable chemical shifts upon P-Ag interaction (K423, R442, R448 and H378; 
additionally V384).  In addition, our crystallography data provide unequivocal proof that the binding 
site proposed by Sandstrom et al(20) for HMBPP is able to interact with negatively charged small 
molecules, and strongly support, alongside the NMR chemical shift data, that this is indeed the site for 
P-Ag interaction. Although we were only able to co-crystallise the non-antigenic citrate and malonate 
molecules in complex with B30.2, the high quality electron density for both molecules in their 
respective structures provides the first glimpse of how such molecules can interact with the 
surrounding residues of the pocket. Although citrate and malonate clearly do not represent biologically 
relevant antigens for Vγ9Vδ2 T cells, importantly they unequivocably confirm the ability of the B30.2 
electropositive pocket to interact with electronegative small molecules. Collectively our data firmly 
establish this pocket as the site for P-Ag interaction on B30.2.  
Our findings have implications for the nature of the triggering mechanism that initiates P-Ag sensing, 
and for the means by which BTN3A1 is able to distinguish P-Ag from non-antigenic small molecules. 
Previously, a conformational change in the B30.2 domain was invoked as a likely consequence of P-
Ag interaction, based on an earlier study by Hsiao et al(27) demonstrating chemical shift perturbations 
in the B30.2 domain on ligand binding, and the observation that soaking of cHDMAPP into apo B30.2 
crystals caused them to dissolve unless they were previously cross-linked with glutaraldehyde (20).  
Our NMR data further strengthens this concept, as we can report exposure to P-Ag resulted in 
chemical shift perturbations to specific, identifiable residues both proximal and distal to the 
electropositive patch, suggesting a conformational change emanating from the P-Ag binding site. 
Distal residues that appear to be influenced include K366, Q369, F390, I391, S413, K419, N428, 
G429 and W431. Although in principle these distal shifts could have resulted from direct P-Ag 
interaction with the residues involved, this was extremely unlikely as rather than being clustered in a 
discrete site(s) on the structure, they were dispersed across its surface. In contrast to P-Ag mediated 
effects, although shifts were observed upon interaction with the non-antigens citrate/malonate, these 
were low in number, small in magnitude, and restricted to residues close to the citrate/malonate 
moieties, consistent with binding but excluding such distal conformational alterations. Importantly, a 
number of these antigen-specific conformational alterations (K366, Q369 and K419) are involved in 
crystal contacts in the apo form of B30.2, consistent with the observation that P-Ag soaking dissolves 
such crystals. The lack of such changes upon citrate/malonate interaction is consistent with the 
observation that citrate/malonate-complexed structures of B30.2 closely match that of the apo form. 
ADP, a common cellular diphosphate, also interacted with the B30.2 and caused chemical shift 
perturbations distal to the proposed binding pocket. However the direction of these shifts differed to 
those observed with immunogenic P-Ags suggesting that a specific B30.2 conformation may be 
required to activate Vγ9/Vδ2 T cells. This model would predict that recent non-immunogenic 
‘phosphoantagonist’ compounds(28) derived from modification of P-Ags are likely to competitively 
inhibit P-Ag-mediated Vγ9/Vδ2 T cell activation by binding to the same electropositive pocket on 
B30.2, but fail to induce the conformational change in B30.2 that results from HMBPP/IPP binding. 
Future studies could address this prediction.    
Finally, the in silico docking simulations we carried out provide a biophysical rationalisation for small 
molecule interaction with B30.2. In addition to confirming that a negatively charged ‘head group’ is a 
key feature of ligands predicted to interact with the B30.2 ligand binding pocket, they highlight the 
potential importance of H381 in forming a hydrogen bonding interaction with the hydroxyl group of 
HMBPP. This is consistent with the critical importance of H381 in HMBPP sensing as highlighted by 
both Adams and Morita groups on the basis of mutational studies(20, 21), and suggest it could be a 
component of a conformational trigger. Although the details of such a mechanism remain unclear, in 
keeping with this suggestion, residues W380-Y382 were unassignable on NMR, suggesting 
considerable flexibility in this loop region in solution, and conversely chemical shits were observed 
upon P-Ag exposure in residue V384, which was not predicted to interact directly with P-Ag in docking 
experiments. Furthermore, mutations to H381 significantly impaired the activation of Vγ9/Vδ2 T cells. 
In contrast to Shippy et al (29), whose model proposed an interaction between Y382 and P-Ag, we 
found that mutations to Y382 had differing effects on Vγ9/Vδ2 T cell activation, depending on the 
particular mutation, and our NMR data suggest that this is due to alterations in conformational change 
induced by P-Ags, which may be due to alterations in the P-Ag binding pocket.     
In summary, our findings support the notion that a specific conformational change in the intracellular 
B30.2 domain of BTN3A1 is triggered as a direct result of P-Ag interaction, and that the ability to 
induce such a conformational change may be a key property that distinguishes antigenic small 
molecules capable of triggering Vγ9/Vδ2 T cell activation from other non-antigenic molecules that 
merely bind to B30.2. In doing so, they provide robust evidence that B30.2 acts as a ‘conformational 
sensor’ to detect intracellular P-Ag exposure. A limitation of the current study is that the nature of how 
this is transmitted to the cell exterior is unclear. There are various mechanisms conceivable, such as 
‘inside-out’ propagation of conformational alterations (20), or alternatively recruitment of additional 
cell-surface proteins to the P-Ag-bound B30.2 domain. Additional structural and molecular studies on 
BTN3A1 may shed light on these issues. In addition, another poorly understood issue that warrants 
further investigation is how extracellular P-Ag can access intracellular compartments, although energy 
dependent processes are clearly involved	 (30). However, as there is strong therapeutic interest in 
Vγ9/Vδ2 T cells, the current study will inform attempts to develop more potent Vγ9/Vδ2 T cell-based 
immunotherapies, including those directed against cancer, specifically highlighting the requirement for 
P-Ag to access intracellular compartments and to induce appropriate conformational alterations in 
BTN3A1. Successful exploitation of Vγ9Vδ2 T cell recognition would complement current 
immunotherapy concepts focussed on αβ T cell recognition that depend on MHC expression for 
efficacy, potentially enabling targeting of tumours where MHC downregulation is relatively common. 
 
 
 
 
 
	
	
 
 
 
 
 
 
 
 
  
Methods 
Cloning, expression and protein purification of BTN3A1-IgV and BTN3A1-B30.2 domains  
Protein production for crystallization studies 
The gene encoding the BTN3A1-B30.2 domain (R322-A513) was cloned into pET26 with a C-terminal 
His tag, and transformed into BL21 (DE3) competent E. coli cells (New England Biolabs). 
Transformed E. coli were cultured at 37oC until an OD600 of 0.4-0.6 was attained. Protein expression 
was induced with 0.5 mM Isopropyl-β-D-1-Thiogalactopyranoside and cells were cultured for a further 
18-20 hours at 18oC. The pelleted bacterial biomass was resuspended into 50mM Sodium phosphate 
pH 7.4, 500mM Sodium chloride, 50mM Imidazole, 0.5mM Tris (2-carboxyethyl) phosphine (TCEP) 
and COmplete EDTA free protease inhibitors (Sigma-Aldrich) and homogenised using an AVESTIN 
EmulsiFlex C3 and centrifuged at 19000rpm/4oC for 30 minutes. The harvested supernatant was 
loaded onto a 5ml Hi-Trap column (GE) overnight. The column was washed with 5 column volumes of 
resuspension buffer to prevent non-specific binding. His-tagged protein was eluted with resuspension 
buffer containing a high concentration of imidazole (300mM) and further purified by size exclusion 
chromatography using a HiLoad 26/60 Superdex 200 column pre-equilibrated with 50mM Sodium 
Phosphate pH 7.4, 150mM Sodium Chloride, 0.5mM TCEP and COmplete EDTA free protease 
inhibitors.  
Protein production for Nuclear Magnetic Resonance spectroscopy studies 
BTN3A1-IgV (S28-V143) and BTN3A1-B30.2 (R322-A513) constructs for NMR experiments were 
overexpressed in BL21 (DE3) E. coli in the presence of M9 minimal media supplemented with 15N 
labelled ammonium chloride, 13C labelled glucose and deuterated water. Further purification steps 
were followed as previously described. BTN3A1-IgV was purified by size exclusion chromatography 
into 20mM MES pH6.5, 50mM NaCl.  BTN3A1-B30.2 was purified by size exclusion chromatography 
into a buffer containing 50mM Sodium Phosphate, 50mM Sodium Chloride, 0.5mM TCEP and 
COmplete EDTA free protease inhibitors (pH 7.4).      
Crystallization 
BTN3A1-B30.2 domain was concentrated with tenfold excess cHDMAPP (Cayman Chemical) to 
20mg/ml and subjected to crystallisation trials with the mosquito robot (TTpLabTech) using the 
hanging-drop vapour diffusion method. Diffraction-grades crystals were grown in drops equilibrated 
against Index (Hampton Research) condition 88 (0.2M Ammonium Citrate tribasic [pH 7.0], 20%w/v 
Polyethylene glycol (PEG) 3,350 [pH 7.0]) and JCSG-plus (Molecular Dimensions) condition 78 (0.2M 
Sodium malonate dibasic monohydrate [pH 7.0], 20%w/v PEG 3,350). Crystals appeared after 5 days 
at 298K.  Prior to data collection crystals were soaked in mother liquor supplemented with increasing 
concentrations of ethylene glycol (10, 20 and 25%) and flash cooled  in liquid nitrogen gas stream. X-
ray diffraction data sets were collected to 1.7Å (BTN3A1-B30.2-citrate) using the ‘in house’ X-ray 
diffraction facility and at 1.6Å (BTN3A1-B30.2-malonate) at the Diamond Light Source (beamline I02). 
X-ray data were integrated and scaled using programs of the XDS suite (31). 
Structural Determination 
The structures were determined using the molecular replacement phasing method with MOLREP 
(32). The previously resolved structure of the BTN3A1-B30.2 domain was used as a search model 
(pdb code 4N7I; Sandstrom et al). Model building and refinement were performed in COOT (33) and 
REFMAC5	 (34), respectively. Water molecules were added iteratively to each model, followed by 
cycles of refinement. The data collection and refinement statistics are summarised in Table S1. The 
stereochemical quality of the atomic models was assessed using PROCHECK (35). Ribbon diagrams 
and molecular surface representations were generated by PyMol (36). The atomic co-ordinates and 
structure factors have been deposited on the Protein Data Bank with accession codes (5LYG 
(BTN3A1-B30.2-malonate) and 5LYK (BTN3A1-B30.2-citrate)).   
Nuclear Magnetic Resonance Spectroscopy 
NMR experiments were performed on 600MHz and 900MHz Oxford Avance III spectrometers 
equipped with TXO (600MHz) and TCI (900MHz) 5mm z-pulse field gradient triple enhanced 
cryogenic probes at 298 K. Sequential assignments were made from TROSY versions of HN(CO)CA, 
HNCA, HN(CO)CACB, HNCACB, HN(CA)CO and HNCO experiments with non-uniform sampling	(37-
39). Phosphoantigen titration experiments with BTN3A1-IgV (0.3mM) and BTN3A1-B30.2 (0.3 mM) 
were performed by Heteronuclear Single Quantum Coherence spectroscopy (HSQC) using 1.5 mM 
IPP (Teu Bio), 1.5 mM HMBPP (Teu Bio) and 1.5 mM cHDMAPP (Cayman Chemicals). Malonate and 
Citrate titrations were performed using 100mM as this was reflective of the relative conditions found in 
the crystallization conditions. The data was acquired using Topspin 3.2.6 (Bruker), the spectra were 
processed using NMRPipe (40) and were analysed using SPARKY(41). 
T cell isolation, culture and activation 
Human peripheral blood mononuclear cells (PBMC) were isolated from heparinised venous blood 
from consented healthy donors (protocol approved by the NRES Committee West Midlands ethical 
board; REC reference 14/WM/1254). Briefly, whole blood was layered over lymphoprep© (Stem Cell 
Technologies) and centrifuged with resulting PBMC used for subsequent experiments. 5 x 105 PBMC 
were cultured for 20 hours in the presence of medium alone, medium supplement with vehicle 
(DMSO; Sigma) or medium supplemented with the indicated concentrations of cHDMAPP, IPP, 
ammonium citrate and sodium malonate. The cell culture medium used was RPMI-1640 media 
supplemented with 2 mM L-glutamine, 1% sodium pyruvate, 50 μg/ml penicillin/streptomycin 
(Invitrogen) and 10% fetal calf serum (Sigma). Vδ2+ T cells were expanded from PBMCs with 5μM 
Zoledronate (Sigma) and subsequent addition of 100 units/mL IL-2 (Biolegend) every three days. 
Cultured PBMC were labelled with aqua viability dye (Biolegend), and then cells were stained for 
surface antigens with antibodies directed against CD3 (UCHT1), CD8 (SK1), CD69 (FN50), CD25 
(2A3); all Biolegend, TCR Vg9 (IMMU360); Beckman Coulter, and TCR Vd2 (123R3); Miltenyi. Cells 
were acquired on an LSR II (Beckton Dickinson) and data analysed with FlowJo V10.1 (TreeStar). 
Tabulated data were analysed and graphed in Graphpad PRISM 7 (Graphpad Software Inc). 
Generation of BTN3A1 B30.2 mutants 
Site directed mutagenesis was performed on both eukaryotic and mammalian expression vectors 
using Q5® High-Fidelity DNA Polymerase (New England Biolabs) according to the manufacturer’s 
instructions. Primers used can be found in Table S2. 
Overexpression of Mutant BTN3A1 and Co-culture assays 
Wildtype and mutant forms of BTN3A1 were reintroduced into BTN3A1 KO HEK239T cells at 0.5μg 
DNAin a transfection mix containing 0.1 mg/mL polyethylenimine supplemented with serum free 
OptiMem (Invitrogen). Transfected cells were treated with 10μM Zoledronate for24 hours and 
HEK293T cells were then co-cultured for a further 18 hours with expanded human Vδ2+ T cells at a 
ratio of 1:1. Cells were then labelled with aqua viability dye and stained with antibodies directed 
against the cell surface markers CD3 (UCHT1), TCR Vγ9 (IMMU360), TCR Vδ2 (123R3), and CD25 
(2A3).  
Molecular modelling studies 
The computational studies were executed by the PC windows 7 with Intel Core i7-4790 /3.6GHz 
microprocessor, 16 GB RAM and 64 Bit operating system. Molecular docking was performed using 
different tools provided by OpenEye Scientific Software (http://www.eyesopen.com). The three-
dimensional crystal structure of the intracellular B30.2 domain of BTN3A1 in complex with cHDMAPP 
was retrieved from the Protein Data Bank (PDB ID: 4N7U). This was used as the receptor and the 
active site was identified on the basis of the bound ligand. Omega2 (OpenEye Scientific Software) 
was used to generate multiple ligand conformers using the default settings	 (42). FRED (fast rigid 
exhaustive docking) rigidly fitted these conformers into the pre-defined binding site and ranks the 
poses by scoring functions	 (43, 44). The VIDA module of the OpenEye toolkit was then used to 
visualise the docked poses within the receptor’s active site and to inspect the docked poses as well 
as identify the main interacting residues. 
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Figure 1 
 
NMR chemical shift perturbation analysis of BTN3A1-IgV domain with HMBPP.  
Overlay of 1H 15N HSQC spectra of 15N-labelled 0.3mM BTN3A1-IgV domain in the absence (black) 
and presence (red) of 1.5 mM HMBPP. The black boxes highlight a close-up view of peaks 
corresponding to BTN3A1- IgV residues (E64, K66, R88, Y127, Q129 and Y134) that have previously 
been implicated in binding HMBPP based on X-ray crystallographic data. 
 
 
 
 
 
 
 
 
Figure 2  
 
 
 
 NMR chemical shift perturbation analysis of BTN3A1-B30.2 intracellular domain with 
cHDMAPP.  
Overlay of 1H 15N HSQC spectra of 15N-labelled 0.3 mM BTN3A1-B30.2 domain in the absence 
(black) and presence (red) of non-labelled 3mM cHDMAPP. The black boxes highlight a close-up 
view of peaks corresponding to selected BTN3A1-B30.2 residues that undergo chemical shift 
perturbation following titration with cHDMAPP (examples include small (S413), medium (G429) and 
large (T432, R442 and K423) chemical shift perturbations).   
 
 
 
 
 
Figure 3  
 
Structural analysis of BTN3A1-B30.2 in complex with malonate and citrate.  
a) BTN3A1-B30.2-malonate complex with the 1.4Å resolution composite omit Fo-Fc electron density 
map for malonate contoured at 2σ (blue). b) BTN3A1-B30.2-citrate complex with the 1.7Å resolution 
composite omit Fo-Fc electron density map for malonate contoured at 2σ (blue).  Residues in close 
proximity to malonate or citrate are shown (ball and stick format). c) Electrostatic potential of the 
BTN3A1-B30.2-malonate complex calculated with DelPhi with the potential scale ranging from -7 (red) 
to +7 (blue) in units of kT/e. d) Electrostatic potential of the BTN3A1-B30.2-citrate complex calculated 
with DelPhi with the potential scale ranging from -7 (red) to +7 (blue) in units of kT/e. e) BTN3A1-
B30.2 binding pocket (green) with the structures of malonate (yellow), citrate (blue) and cHDMAPP 
(red) superimposed. f-h) Structures of BTN3A1-B30.2 bound to cHDMAPP (f), malonate (g) and 
citrate (h). I) Superimposition of the Cα backbones for BTN3A1-B30.2 (green), BTN3A1-B30.2-
malonate complex (yellow),  BTN3A1-B30.2-citrate complex (blue) and BTN3A1-B30.2-cDHAMPP 
complex (red). BTN3A1-B30.2 residues that mediate hydrogen bonding interactions (black dashed 
lines) with each ligand are shown (ball and stick format). Red spheres represent water molecules.  
 
 
Figure 4 
 Chemical shift perturbation mapping of the cHDMAPP, HMBPP and IPP binding sites on 
BTN3A1-B30.2 domain.  
a) Surface mapping of perturbed residues of BTN3A1-B30.2 (shown as stick format) upon cHDMAPP 
binding. Residues are coloured based on small (cyan), medium (orange) and large (red) chemical 
shift perturbations. cHDMAPP is shown as stick format. b) Surface mapping of perturbed residues of 
BTN3A1-B30.2 (shown as stick format) upon HMBPP binding. Residues are coloured based on small 
(cyan), medium (orange) and large (red) chemical shift perturbations. HMBPP is shown as stick 
format. c)  Surface mapping of perturbed residues of BTN3A1-B30.2 (shown as stick format) upon 
IPP binding. Residues are coloured based on small (cyan), medium (orange) and large (red) chemical 
shift perturbations. IPP is shown as stick format. 
 
Figure 5 
 NMR chemical shift perturbation analysis of BTN3A1-B30.2 domain with malonate. 
a) Overlay of 1H 15N HSQC spectra of 15N-labelled 0.3mM BTN3A1-B30.2 domain in the absence 
(black) and presence of 100mM sodium malonate (red). Black boxes highlight a close-up view of 
peaks corresponding to BTN3A1-B30.2 residues that undergo chemical shifts upon 
HMBPP/cHDMAPP binding. b) Surface mapping of perturbed residues of B30.2 (shown as stick 
format) upon malonate binding. Residues are coloured based on small (cyan), medium (orange) and 
large (red) chemical shift perturbations. Malonate is shown as stick format. 
 
 
 
Figure 6  
 B30.2 domain of human BTN3A1 selectively binds small negatively charged moieties but only 
a limited set of these molecules directly activates human Vγ9/Vδ2
+ 
T cells.                                  
a) PBMCs were stained with antibodies directed against surface antigens for CD3, TCR Vγ9, TCR 
Vδ2 and CD8. (n=3). b) PBMCs were incubated for 20 hours with the indicated concentration of P-Ags 
or medium and Vγ9/Vδ2+ T cells were assessed for the expression of CD69 and CD25. c) As in b), but 
PBMCs incubated with the indicated concentrations of the B30.2 binding molecules citrate and 
malonate. d) CD8+ T cells were assessed for the upregulation of CD69 following titration with 
indicated compounds. e) Vγ9/Vδ2+ T cells were assessed for the upregulation of CD69 and CD25 
following titration with indicated compounds. Error bars indicate means ± SEM.  
 
 
 
 
 
 
 
Figure 7 
  
In silico docking of small molecule B30.2 domain binders.  
a-b) Docking of cHDMAPP (a) and IPP (b), into the apo B30.2 domain structure showing important 
hydrogen bonding interactions (dashed black lines) with three key arginine residues (R442, R448 and 
R499). The hydroxyl group of cHDMAPP also mediates an additional hydrogen bonding interaction 
with H381. Red spheres represent water molecules. 
  
Figure 8 
 
Figure 8. Mutations of BTN3A1-B30.2 H381 and Y382 residues abrogate Vγ9
+
/Vδ2
+ 
T cell 
activation. 
(a) Representative and summary data from expanded human Vδ2+ T cells incubated in the presence 
of HEK293T cells subjected to an empty vector (Ev) or BTN3A1 CRISP/Cas9 (BTN3A1-KO) construct 
and then transiently transfected with BTN3A1 Wild Type construct pulsed with 10 μM zoledronate or 
medium and assessed for CD25 expression. (b) Representative and summary data from expanded 
human Vδ2+ T cells assessed for CD25 expression after incubation with BTN3A1-KO HEK293T cells 
transiently transfected with H381 and Y382 mutant BTN3A1 constructs and pulsed with 10 μM 
zoledronate. Summary data in (b), depicts each mutant and mock control CD25+ expression levels on 
Vδ2+ T cells normalised to the total CD25+ expression obtained for wild type BTN3A1 activation. n = 3. 
Error bars indicate means ± SEM; ns = not significant, * P < 0.05; ** P < 0.01; *** P < 0.001, **** P < 
0.001; p-values were determined by one-way ANOVA with Tukey’s post hoc testing. 
 
